This Specialized Resource will provide chemical expertise and produce imaging agents that are not commercially available. These agents will be a) rigorously tested so as to conform to strict standards (by being synthesized under standardized conditions in technically adequate ways);b) analyzed according to a standard protocol prior to use;and c) synthesized in sufficient amounts for in vivo use. They will be available to all Project researchers. As it has in the past, this Resource will also conduct its own research in order to further improve synthetic conditions, and to design fluorochromes, sensors, tags, linkers and nanoparticulate carriers.
The specific aims of this Specialized Resource are to synthesize and provide: 1) an array of new fluorochromes, fluorescently labeled reagents, sensors, and coupling reagents;2) nanomaterial based imaging agents;and 3) radiochemistry expertise and novel ''^F-imaging agents. The existence of this Specialized Resource has a number of benefits to the overall Program, these include: a) access to cutting edge synthetic, bioconjugate and analytical chemistry;b) access to radiochemistry;c) access to well validated imaging compounds that are not commercially available;d) capabilities for scaling up the synthesis of novel compounds;and e) access to specific training. By centralizing personnel, resources and supplies, the Chemistry Resource is able to provide these functions extremely efficiently and at a reduced overall cost.

Public Health Relevance

This Chemistry Resource is an integral part of this P50 Program, providing essential compounds that are not commercially available to all Projects and Developmental Projects. This Resource also scales up imaging agents for in vivo use and carries out rigorous quality assurance.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Dubach, J Matthew; Kim, Eunha; Yang, Katherine et al. (2017) Quantitating drug-target engagement in single cells in vitro and in vivo. Nat Chem Biol 13:168-173
Vinegoni, Claudio; Fumene Feruglio, Paolo; Brand, Christian et al. (2017) Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging. Nat Protoc 12:1472-1497
Iaconelli, Jonathan; Lalonde, Jasmin; Watmuff, Bradley et al. (2017) Lysine Deacetylation by HDAC6 Regulates the Kinase Activity of AKT in Human Neural Progenitor Cells. ACS Chem Biol 12:2139-2148
Arlauckas, Sean P; Garris, Christopher S; Kohler, Rainer H et al. (2017) In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 9:
Miller, Miles A; Weissleder, Ralph (2017) Imaging the pharmacology of nanomaterials by intravital microscopy: Toward understanding their biological behavior. Adv Drug Deliv Rev 113:61-86
Engblom, Camilla; Pfirschke, Christina; Zilionis, Rapolas et al. (2017) Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:
Miller, Miles A; Askevold, Bjorn; Mikula, Hannes et al. (2017) Nano-palladium is a cellular catalyst for in vivo chemistry. Nat Commun 8:15906
Pucci, Ferdinando; Garris, Christopher; Lai, Charles P et al. (2016) SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science 352:242-6
Roy, Jeremy; Kim, Bongki; Hill, Eric et al. (2016) Tyrosine kinase-mediated axial motility of basal cells revealed by intravital imaging. Nat Commun 7:10666
Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44:343-54

Showing the most recent 10 out of 316 publications